Sihai network

Where can cervical cancer vaccine be made in China? The best vaccination age of cervical cancer vacc

Cervical cancer has become one of the major killers of women's health. Cervical cancer is the third common malignant tumor in the world, next to breast cancer and colorectal cancer. Therefore, vaccination against cervical cancer is very helpful for the prevention of cervical cancer. So where can we vaccinate in China? What is the best age for vaccination against cervical cancer?

Where does cervical cancer vaccine hit home?

It is understood that at present 'sirishi' has entered the supplementary procurement procedure of class II vaccine at provincial level in Jiangsu Province, and will be purchased by each district on the platform after completion. The vaccination sites of 'sirishi' are community hospitals and community health service centers in each city. The specific vaccination plan will be announced to the public after being determined. Before the national day, Jiangsu residents can get the cervical cancer vaccine at home.

According to the instructions for the use of 'Hirsch', Hirsch is used in mainland China to vaccinate 9-25-year-old women, requiring a total of three injections. According to GlaxoSmithKline, "Hirsch" is currently priced at 580 yuan / piece in the provinces that have won the bid. However, considering the different policies of each province, the final payment of vaccinators will vary, which is expected to be lower than the total price of Hong Kong vaccinations.

In addition, worldwide, two pharmaceutical companies approved to market cervical cancer vaccine are Merck and GlaxoSmithKline. Hirsch is a bivalent vaccine that can prevent 70% of cervical cancer. In May this year, MSD also announced that its quadrivalent cervical cancer vaccine, jiadaxiu, was approved in China and approved for women aged 20-45 in mainland China. However, there is no timetable for when 'Gaddafi' will be vaccinated.

In recent years, many domestic enterprises have started the research and development of cervical cancer vaccine, which is expected to be approved for listing in recent years.

The domestic price of cervical cancer vaccine in 2018 listed in the mainland will have obvious advantages in pricing. If the vaccination unit implements the zero price difference pricing, the vaccination price of three doses of vaccine will be 1740 yuan. According to the data of meizhao physical examination, the current price of the vaccination in Hong Kong is 2500 Hong Kong dollars (about 2153 yuan), while the price of the 4th and 9th price of the vaccination in MSD is 2700 yuan respectively Hong Kong dollars (about 2325 yuan) and 4500 Hong Kong dollars (about 3875 yuan).

However, Hirsch is likely to encounter a strong rival in the Chinese market soon. In May this year, jiadaxiu, the 4-valent cervical cancer vaccine of mosadong, was in the stage of 'approval completed - to be certified'. According to another report, the 4-price HPV vaccine of mosadong has been successfully won in Yunnan Province, with the bid price of 798 yuan / dose, which means that the product will also be available for sale in the near future.

In the global market, Hirsch of GSK has always been inferior to jiadaxiu produced by MSD, which has a long-term market share of more than 90% in the global market. In the second half of last year, Hirsch withdrew from the U.S. market because of 'extremely low market demand'.

Currently, the list of 17 winning provinces disclosed by GSK does not include beishangguang and the relatively developed provinces and regions around the three regions. In this regard, GSK said: 'the local centers for Disease Control and prevention decide whether to win the bid or not. As long as there is a bidding opportunity, we will continue to do our best. '

How old is cervical cancer vaccine suitable for?

According to the instructions, the vaccine is suitable for women aged 9 to 25. Experts suggest that married, pregnant and sexually active women can be vaccinated against cervical cancer, and the best effect is to vaccinate before having sex. The vaccine will be immunized with three doses according to the vaccination procedures of 0, 1 and 6. That is to say, the interval between the first dose and the second dose is one month, the interval between the second dose and the third dose is five months, and it will take half a year for the three doses to be inoculated.

Cervical cancer is a common malignant tumor that seriously threatens women's health. Every year, there are 100000 new cases and 30000 deaths in China, among which the third highest incidence of cancer is among women aged 15-44. Therefore, while carrying out cervical cancer screening, cervical cancer vaccination will significantly reduce the incidence of cervical cancer and its precancerous lesions, thus reducing the burden of disease.

GlaxoSmithKline said that the company is now applying to expand the scope of age use, and it is expected that the population over 25 years old will receive 2-valent cervical cancer vaccine next year.